Revolution Medicines Net Worth
Revolution Medicines Net Worth Breakdown | RVMD |
Revolution Medicines Net Worth Analysis
Revolution Medicines' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Revolution Medicines' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Revolution Medicines' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Revolution Medicines' net worth analysis. One common approach is to calculate Revolution Medicines' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Revolution Medicines' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Revolution Medicines' net worth. This approach calculates the present value of Revolution Medicines' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Revolution Medicines' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Revolution Medicines' net worth. This involves comparing Revolution Medicines' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Revolution Medicines' net worth relative to its peers.
Enterprise Value |
|
To determine if Revolution Medicines is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Revolution Medicines' net worth research are outlined below:
| The company reported the previous year's revenue of 11.58 M. Net Loss for the year was (436.37 M) with loss before overhead, payroll, taxes, and interest of (217.69 M). | |
| Revolution Medicines currently holds about 461.43 M in cash with (350.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.26. | |
| Revolution Medicines has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Wellington Management Group LLP Reduces Stake in Revolution Medicines Inc |
Revolution Medicines Quarterly Good Will |
|
Revolution Medicines uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Revolution Medicines. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Revolution Medicines' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Revolution Medicines Target Price Consensus
Revolution target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Revolution Medicines' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 15 | Strong Buy |
Most Revolution analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Revolution stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Revolution Medicines, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationRevolution Medicines Target Price Projection
Revolution Medicines' current and average target prices are 59.33 and 36.00, respectively. The current price of Revolution Medicines is the price at which Revolution Medicines is currently trading. On the other hand, Revolution Medicines' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Revolution Medicines Market Quote on 13th of November 2024
Target Price
Analyst Consensus On Revolution Medicines Target Price
Know Revolution Medicines' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Revolution Medicines is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Revolution Medicines backward and forwards among themselves. Revolution Medicines' institutional investor refers to the entity that pools money to purchase Revolution Medicines' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 5.1 M | Bellevue Group Ag | 2024-06-30 | 5 M | Hhg Plc | 2024-06-30 | 4.6 M | Casdin Capital, Llc | 2024-06-30 | 4.4 M | Boxer Capital Llc | 2024-06-30 | 4.3 M | Geode Capital Management, Llc | 2024-06-30 | 3.3 M | Woodline Partners Lp | 2024-06-30 | 3.3 M | Jpmorgan Chase & Co | 2024-06-30 | 3.1 M | Deerfield Management Co | 2024-06-30 | 3.1 M | Vanguard Group Inc | 2024-06-30 | 14.4 M | Wellington Management Company Llp | 2024-06-30 | 13.7 M |
Follow Revolution Medicines' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 10.19 B.Market Cap |
|
Project Revolution Medicines' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.25) | (0.27) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.24) | (0.25) |
When accessing Revolution Medicines' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Revolution Medicines' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Revolution Medicines' profitability and make more informed investment decisions.
Please note, the presentation of Revolution Medicines' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Revolution Medicines' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Revolution Medicines' management manipulating its earnings.
Evaluate Revolution Medicines' management efficiency
Revolution Medicines has return on total asset (ROA) of (0.2856) % which means that it has lost $0.2856 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4718) %, meaning that it created substantial loss on money invested by shareholders. Revolution Medicines' management efficiency ratios could be used to measure how well Revolution Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of November 13, 2024, Return On Tangible Assets is expected to decline to -0.23. In addition to that, Return On Capital Employed is expected to decline to -0.27. At present, Revolution Medicines' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 7.4 M, whereas Other Assets are forecasted to decline to 0.95.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 16.14 | 16.95 | |
| Tangible Book Value Per Share | 15.50 | 16.28 | |
| Enterprise Value Over EBITDA | (6.12) | (6.43) | |
| Price Book Value Ratio | 1.78 | 1.69 | |
| Enterprise Value Multiple | (6.12) | (6.43) | |
| Price Fair Value | 1.78 | 1.69 | |
| Enterprise Value | 2.6 B | 1.4 B |
Revolution Medicines has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 11.8 K | Revenue 742 K | Quarterly Revenue Growth (0.95) | Revenue Per Share 0.005 | Return On Equity (0.47) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Revolution Medicines insiders, such as employees or executives, is commonly permitted as long as it does not rely on Revolution Medicines' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Revolution Medicines insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Revolution Medicines Corporate Filings
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 28th of June 2024 Other Reports | ViewVerify |
Revolution Medicines Earnings per Share Projection vs Actual
Revolution Medicines Corporate Management
| David Pompliano | Founding Officer | Profile | |
| Jack Anders | Chief Officer | Profile | |
| Walter Reiher | Chief Officer | Profile | |
| Path FRCP | Pres RD | Profile | |
| Margaret JD | Chief Officer | Profile | |
| Michael Fischbach | Academic Board | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revolution Medicines. If investors know Revolution will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revolution Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.59) | Revenue Per Share 0.005 | Quarterly Revenue Growth (0.95) | Return On Assets (0.29) | Return On Equity (0.47) |
The market value of Revolution Medicines is measured differently than its book value, which is the value of Revolution that is recorded on the company's balance sheet. Investors also form their own opinion of Revolution Medicines' value that differs from its market value or its book value, called intrinsic value, which is Revolution Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revolution Medicines' market value can be influenced by many factors that don't directly affect Revolution Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revolution Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revolution Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revolution Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.